The Global Health Body Sounds Alert Over Critical Lack of Weight-Loss Injections

Fewer than one in 10 patients who could benefit from obesity jabs including Wegovy are able to get them, states the global health agency as it issues its inaugural recommendations on the medications.

Given over a billion people worldwide currently obese, it is calling for more widespread and fairer access to GLP-1 medication.

Based on forecasts, more than two billion could be living with obesity by 2030 unless action is taken.

"The latest guidelines affirms that obesity is a long-term condition that can be managed with holistic and continuous support," remarked the agency's head Tedros Adhanom Ghebreyesus.

Substantial prices, insufficient output, and logistical bottlenecks are key barriers to broad availability to the treatments that can aid individuals in losing significant body mass, notes the organization.

Skinny Jab Scarcity

Despite the current most optimistic case, the supply of GLP-1 therapies could only cover around 100 million people – fewer than 10% of the global need, as stated by the health organization.

The guideline urges countries and companies to widen access, via approaches including voluntary licensing.

The intellectual property rights on semaglutide – the primary component of Novo Nordisk's Wegovy – is scheduled to end in a number of nations in 2026.

How Obesity Injections Operate

GLP-1 drugs replicate a body's own hormone to reduce digestion speed, suppress the appetite and enhance the sense of being full so individuals consume fewer calories.

People typically start to lose weight after several weeks of starting on the regular doses.

Studies points to patients may see weight return within a year of halting the drug, when their normal food cravings resume.

To be above a healthy weight raises your chance for developing diseases, including diabetes, cardiovascular issues, brain attack, and certain malignancies.

Excess weight concerns individuals in every country and was responsible for 3.7 million deaths worldwide in 2024, according to the health agency.